Cpd-564 was identified as a METTL3 inhibitor exhibiting better protective effects against cisplatin-induced and ischemia/reperfusion-induced renal injury and inflammation compared with S-adenosyl-L-homocysteine, An effective inhibitor of SAM-dependent methyltransferase16, 44. Here, METTL3 is linked to ischemia.